Drug Trial Radar · NCT00679523
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
Last checked: Nov 20, 2026Latest source record: Nov 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Nov 2005
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety and efficacy of 5.0% and 7.5% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.
Conditions
- Onychomycosis
Interventions
AN2690 Solution, 5.0%Drug
Once daily application for 180 days
AN2690 Solution, 7.5%Drug
Once daily application for 180 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- A calculated endpoint of treatment response at Day 180 comprised of the ISGA, clear nail growth and fungal culture resultsTime frame: Day 180
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Unidad de Investigación en Salud (UIS)
Chihuahua City, Mexico
Hospital "Dr. Angel Leaño"
Guadalajara, Mexico
Instituto Dermatologico Jalisciense
Guadalajara, Mexico
Centro Dermatologico Pascua
Mexico City, Mexico
CIF-BIOTEC Medica Sur.
Mexico City, Mexico
IMIC
Mexico City, Mexico
Hospital Universitario Dr. José Eleuterio González
Monterrey, Mexico
MIRC / OCA Hospital
Monterrey, Mexico
ISSEMYM
Toluca, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.